Seizure localization for epilepsy surgery using high frequency electrophysiological markers

使用高频电生理标记进行癫痫手术的癫痫发作定位

基本信息

  • 批准号:
    10570953
  • 负责人:
  • 金额:
    $ 34.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-03-15 至 2026-02-28
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT In the most severe cases of epilepsy, where seizures persist despite multiple trials of anti-seizure medications, patients may benefit from surgical removal of seizure-generating brain tissue. Prior to surgery, electrodes are often implanted directly into or onto the patient’s brain and are used to continuously record electrical brain activity over days. This is done to capture seizure activity and determine its point of origin, i.e. the seizure onset zone. If the seizure onset zone is identified, clinicians then use this information, in combination with the results of brain imaging and other testing, to guide removal of the corresponding brain tissue. While epilepsy surgery may lead to seizure freedom, 70-90% of surgery patients remain on anti-seizure medications and roughly 50% of patients continue to have seizures. The long-term goal of this work is to improve the outcomes of patients undergoing epilepsy surgery by developing more accurate methods to localize seizure-generating tissue. High frequency oscillations (HFOs) have garnered considerable excitement for their potential to identify and localize epileptogenic brain tissue. HFOs are short bursts of high-frequency electrical activity that occur in the brains of patients with epilepsy. They occur more frequently in the epileptogenic zone (EZ, the hypothetical area that must be excised to attain post-operative seizure freedom), and surgically removing HFO-generating brain tissue increases the likelihood of seizure freedom. While ongoing clinical trials are attempting to assess their prospective value for epilepsy surgery planning, there are multiple barriers to their widespread use. While group-level results are robust, HFO analysis is not yet predictive for single subjects. Recordings lack the sensitivity to reliably measure HFOs in every patient, and the occurrence of non-epileptic HFOs confounds the results. Therefore, HFOs are poised to revolutionize epilepsy surgery, but there is a critical need to optimize their measurement and maximize single-subject accuracy. The overall objective of this proposal is to improve EZ localization accuracy through systematic determination of the optimal HFO measurement methodology, coupled with novel, robust methods for HFO analysis. The rationale is that developing these novel methods with improved measurement techniques will increase the accuracy and robustness of HFOs as a biomarker of the seizure onset zone, thus improving the surgical management of epilepsy. To attain our objective, we will pursue three specific aims: (1) Demonstrate that electrode size is a crucial factor in HFO measurement. (2) Develop an automated method for patient-specific localization of the EZ based on HFOs. (3) Evaluate the effects of electrode size and HFO analysis method on EZ localization. The proposed research is significant because it will provide specific recommendations for the measurement and analysis of HFOs, enabling accurate, detailed localization of epileptogenic brain tissue. The expected outcome of this work is that it will guide surgeons in choosing which brain regions to remove and will increase the pool of potential surgical candidates. Overall, this will have a positive impact by leading to a greater chance of seizure freedom and improved quality of life for patients with the most severe cases of epilepsy.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Beth Ann Lopour其他文献

Beth Ann Lopour的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Beth Ann Lopour', 18)}}的其他基金

Bridging the micro and macro scales of seizure dynamics
连接癫痫动力学的微观和宏观尺度
  • 批准号:
    10574151
  • 财政年份:
    2022
  • 资助金额:
    $ 34.24万
  • 项目类别:
Seizure localization for epilepsy surgery using high frequency electrophysiological markers
使用高频电生理标记进行癫痫手术的癫痫发作定位
  • 批准号:
    10368114
  • 财政年份:
    2021
  • 资助金额:
    $ 34.24万
  • 项目类别:
Seizure localization for epilepsy surgery using high frequency electrophysiological markers
使用高频电生理标记进行癫痫手术的癫痫发作定位
  • 批准号:
    10211944
  • 财政年份:
    2021
  • 资助金额:
    $ 34.24万
  • 项目类别:
Seizure localization for epilepsy surgery using high frequency electrophysiological markers
使用高频电生理标记进行癫痫手术的癫痫发作定位
  • 批准号:
    10606373
  • 财政年份:
    2021
  • 资助金额:
    $ 34.24万
  • 项目类别:

相似海外基金

Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10004277
  • 财政年份:
    2020
  • 资助金额:
    $ 34.24万
  • 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10475298
  • 财政年份:
    2020
  • 资助金额:
    $ 34.24万
  • 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10693904
  • 财政年份:
    2020
  • 资助金额:
    $ 34.24万
  • 项目类别:
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
  • 批准号:
    10013749
  • 财政年份:
    2020
  • 资助金额:
    $ 34.24万
  • 项目类别:
Study on how anticonvulsants affect car driving
抗惊厥药如何影响汽车驾驶的研究
  • 批准号:
    20K17977
  • 财政年份:
    2020
  • 资助金额:
    $ 34.24万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
  • 批准号:
    10266034
  • 财政年份:
    2020
  • 资助金额:
    $ 34.24万
  • 项目类别:
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
  • 批准号:
    10475109
  • 财政年份:
    2020
  • 资助金额:
    $ 34.24万
  • 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10248384
  • 财政年份:
    2020
  • 资助金额:
    $ 34.24万
  • 项目类别:
Prevention of neuropathic pain by antidepressants and anticonvulsants: in vivo patch-clamp analysis
抗抑郁药和抗惊厥药预防神经性疼痛:体内膜片钳分析
  • 批准号:
    24592355
  • 财政年份:
    2012
  • 资助金额:
    $ 34.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Anticonvulsants, ischemic seizures and regeneration in the immature brain
抗惊厥药、缺血性癫痫发作和未成熟大脑的再生
  • 批准号:
    8492175
  • 财政年份:
    2009
  • 资助金额:
    $ 34.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了